Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.

Goñi F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta P, Wisniewski T.

J Neuroinflammation. 2013 Dec 13;10:150. doi: 10.1186/1742-2094-10-150.

2.

Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.

Goñi F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T.

PLoS One. 2010 Oct 13;5(10):e13391. doi: 10.1371/journal.pone.0013391.

3.

Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Wisniewski T, Boutajangout A.

Brain Struct Funct. 2010 Mar;214(2-3):201-18. doi: 10.1007/s00429-009-0236-2. Epub 2009 Dec 10. Review.

4.

Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, Wisniewski T.

J Neurochem. 2014 Feb;128(4):577-91. doi: 10.1111/jnc.12484. Epub 2013 Nov 6.

5.

Vaccination as a therapeutic approach to Alzheimer's disease.

Wisniewski T, Boutajangout A.

Mt Sinai J Med. 2010 Jan-Feb;77(1):17-31. doi: 10.1002/msj.20156. Review.

6.

Tau passive immunization inhibits not only tau but also Aβ pathology.

Dai CL, Tung YC, Liu F, Gong CX, Iqbal K.

Alzheimers Res Ther. 2017 Jan 10;9(1):1. doi: 10.1186/s13195-016-0227-5.

7.

Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease.

Minami SS, Sidahmed E, Aid S, Shimoji M, Niikura T, Mocchetti I, Rebeck GW, Prendergast JS, Dealwis C, Wetzel R, Bosetti F, Matsuoka Y, Hoe HS, Turner RS.

J Neuroinflammation. 2010 Sep 28;7:57. doi: 10.1186/1742-2094-7-57.

8.

Immunotherapeutic approaches for Alzheimer's disease.

Wisniewski T, Goñi F.

Neuron. 2015 Mar 18;85(6):1162-76. doi: 10.1016/j.neuron.2014.12.064. Review.

9.

Immunotherapy for Alzheimer's disease.

Wisniewski T, Goñi F.

Biochem Pharmacol. 2014 Apr 15;88(4):499-507. doi: 10.1016/j.bcp.2013.12.020. Epub 2014 Jan 9. Review.

10.

Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.

Boutajangout A, Wisniewski T.

Gerontology. 2014;60(5):381-5. doi: 10.1159/000358875. Epub 2014 Apr 8. Review.

11.

Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice.

Rasool S, Martinez-Coria H, Milton S, Glabe CG.

Mol Neurobiol. 2013 Dec;48(3):931-40. doi: 10.1007/s12035-013-8478-7. Epub 2013 Jun 15.

PMID:
23771815
12.

Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.

Scholtzova H, Chianchiano P, Pan J, Sun Y, Goñi F, Mehta PD, Wisniewski T.

Acta Neuropathol Commun. 2014 Sep 2;2:101. doi: 10.1186/s40478-014-0101-2.

13.

[Development of antibodies for immunotherapy of Alzheimer's disease].

Matsumoto SE, Jin H, Takeda K, Hasegawa Y, Motoi Y, Hattori N, Tabira T.

Rinsho Shinkeigaku. 2012;52(11):1168-70. Japanese.

PMID:
23196552
14.

A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.

Hoogerhout P, Kamphuis W, Brugghe HF, Sluijs JA, Timmermans HA, Westdijk J, Zomer G, Boog CJ, Hol EM, van den Dobbelsteen GP.

PLoS One. 2011 Apr 19;6(4):e19110. doi: 10.1371/journal.pone.0019110.

15.

Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.

Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, Wu J, Oddo S.

J Neurosci. 2015 Oct 14;35(41):14042-56. doi: 10.1523/JNEUROSCI.2781-15.2015.

16.

Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.

Manczak M, Reddy PH.

Hum Mol Genet. 2012 Dec 1;21(23):5131-46. doi: 10.1093/hmg/dds360. Epub 2012 Aug 27.

17.

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.

J Neurochem. 2007 Aug;102(4):1053-63. Epub 2007 Apr 30.

18.

Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.

Saul A, Sprenger F, Bayer TA, Wirths O.

Neurobiol Aging. 2013 Nov;34(11):2564-73. doi: 10.1016/j.neurobiolaging.2013.05.003. Epub 2013 Jun 5.

PMID:
23747045
20.

High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.

Phivilay A, Julien C, Tremblay C, Berthiaume L, Julien P, Giguère Y, Calon F.

Neuroscience. 2009 Mar 3;159(1):296-307. doi: 10.1016/j.neuroscience.2008.12.006. Epub 2008 Dec 14.

PMID:
19135506

Supplemental Content

Support Center